健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/08/31已确认可信度 88%23天前The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
0.72
健康2026/09/23@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2027/03/31预估延期3个月可信度 77%189天后Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.67
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/03/31已确认可信度 87%176天前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.67
健康2026/09/23@HealthDesk
Eli Lilly Becomes the First Drugmaker Worth $1 Trillion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2025/11/21已确认可信度 87%306天前BioPharma Dive^[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's^[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.
Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.
0.63
健康2026/09/23@HealthDesk
礼来2026年第三季度财报电话会议
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/10/29 14:00预估可信度 71%36天后礼来尚未确认日期（截至2026年9月22日，没有发布“礼来确认2026年第三季度业绩发布日期及电话会议”的公告；第二季度的公告于7月22日发布，定于8月5日）。Public.com^[2]和Nasdaq^[3]将第三季度财报列为“预计”于2026年10月29日“开盘前”发布，这与礼来一贯的节奏（2025年第三季度于2025年10月30日公布）以及其电话会议“将于美东时间上午10点开始”的惯例相符——因此定为2026年10月29日10:00 ET（14:00 UTC），在礼来发布确认公告前均为估计时间。
礼来预计将于10月29日公布2026年第三季度业绩，并照例在美东时间上午10点召开电话会议。此前第二季度营收在Mounjaro和Zepbound带动下增长48%至230亿美元，公司将2026年全年营收指引上调至850亿至870亿美元。
0.62
企业2026/09/23@HealthDesk
J&J Completes Its $1 Billion Acquisition of Firefly Bio
South San Francisco, San Mateo County, California, United StatesJohnson & Johnson…
开始于 2026/07/29已确认可信度 87%56天前"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ^[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".
Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.
$1B
0.62
健康2026/09/23@HealthDesk
礼来在休斯敦Generation Park动工建设65亿美元Foundayo工厂
Eli Lilly…North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United States
开始于 2026/09/21已确认可信度 84%前天礼来的新闻稿标注日期为“HOUSTON^[4], Sept. 21, 2026”，并称礼来“今日在德克萨斯州休斯敦动工”；Community Impact^[2]报道动工仪式于9月21日举行。
这座占地236英亩的工厂将生产礼来减重药Foundayo的活性成分，将带来600多个长期岗位和约4,000个建筑岗位。礼来预计2030年前投产。
$6.5B
0.60
健康2026/09/20@HealthDesk
MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out
Sanofi…Paris, Grand Paris, France
开始于 2028/03/13预估可信度 50%1.5年后ClinicalTrials.gov^[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m
0.59
健康2026/09/23@HealthDesk
FDA批准礼来Inluriyo联合Verzenio用于ESR1突变乳腺癌
Eli Lilly…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States
开始于 2026/09/18已确认可信度 85%5天前礼来的新闻稿标注发稿地与日期为“印第安纳波利斯，2026年9月18日”，并称公司“今日宣布美国食品药品监督管理局（FDA^[4]）已给予完全批准”；FDA自身的公告也将批准日期列为2026年9月18日。
这一全口服组合在EMBER-3试验中将ESR1突变患者的中位无进展生存期从5.5个月翻倍至11.1个月。这是Inluriyo不到一年内获得的第二项FDA批准。
0.59
健康2026/09/23@HealthDesk
Abbott Settles DOJ Infant Formula Claims for $385 Million
Abbott Laboratories…Sturgis, Saint Joseph County, Michigan, 49091, United States
开始于 2026/09/14已确认可信度 88%9天前The release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]
Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.
$385M
0.58
企业2026/09/23@HealthDesk
Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
开始于 2026/09/11已确认可信度 82%12天前The disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's^[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.
Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.
$20B
0.58
健康2026/09/23@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
开始于 2026/01/08已确认可信度 86%258天前J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.57

Lilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]

开始: 2026年5月26日可信度 90%来自来源

Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion

Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.

On 26 May 2026 Lilly announced agreements to acquire Curevo, LimmaTech Biologics and Vaccine Company, expanding its research into infectious disease^[1]
Curevo shareholders could receive up to $1.5 billion, LimmaTech up to $780 million and Vaccine Company up to $1.55 billion, all in cash including milestone payments; the total could reach $3.83 billion^[1][2]
Curevo's amezosvatein, a shingles vaccine, matched the standard of care's immune response in a Phase 2 head-to-head trial and cut side effects such as fatigue, chills and injection-site pain by more than half^[1]
LimmaTech's lead program LTB-SA7 is a Phase 1 vaccine against Staphylococcus aureus, the leading cause of surgical-site infection; it also targets gonorrhoea and chlamydia^[1]
Vaccine Company's In Vivo Nanoparticle technology leads with a five-antigen, Phase 1-ready Epstein-Barr virus vaccine, a virus linked to multiple sclerosis and several cancers^[1]
Lilly did not disclose the upfront payments, and the three deals brought its announced acquisitions in 2026 to 10^[2][3]
The deals are subject to the Hart-Scott-Rodino antitrust waiting period and other customary closing conditions^[1]

@HealthDesk

价格 $3.8B

参考资料 5可信度 87%

第一项始终是图钉的来源。总体可信度是各份资料对上方所用开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半。

[1]90%
prnewswire.com/news-releases/lilly-announces-three-acquisitions-to-build-infectious-disease-portfolio-302781404.html
prnewswire.com· 发布于 2026年9月23日· 开始 2026年5月26日 ✓· 占评分 28%
Lilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".
[2]90%
Eli Lilly's Vaccine Acquisitions Signal a Strategy of Growth in New Areas
medcitynews.com· 发表于 2026年5月26日· 占评分 18%
MedCity News, 26 May 2026: the three deals could reach up to $3.83 billion in total, the per-company terms, the Phase 2 comparison with Shingrix and that they bring Lilly's 2026 acquisitions to 10.
[3]88%
Lilly dives into vaccine research with 3 biotech buyouts
biopharmadive.com· 发表于 2026年5月26日· 占评分 18%
BioPharma Dive, 26 May 2026: Lilly agreed on Tuesday to buy the three private vaccine developers for up to nearly $4 billion; upfront payments were not disclosed.
[4]85%
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
cnbc.com· 发表于 2026年5月26日· 占评分 18%
CNBC, 26 May 2026: the deals for Curevo, LimmaTech Biologics and Vaccine Company at $1.5 billion, $780 million and $1.55 billion, and the stock's reaction.
[5]82%
Lilly will buy 3 vaccine firms in 'power move'
cen.acs.org· 发表于 2026年5月26日· 占评分 18%
C&EN, 26 May 2026: Lilly is spending up to $3.8 billion on three vaccine makers; describes each company's lead candidate.^[1]

建议更正

有遗漏或错误吗？用你自己的话说明：能佐证此图钉的链接、不同的开始或结束日期及理由，或缺失、有误的信息。AI 会对照此图钉的来源进行核实，搜索更好的来源，并添加任何支持你说法的页面。图钉自身的来源仍然最重要。

串

回应这个图钉

1Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion开始时为 US$1,064.74

健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/08/31已确认可信度 88%23天前The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
0.72
健康2026/09/23@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2027/03/31预估延期3个月可信度 77%189天后Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.67
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/03/31已确认可信度 87%176天前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.67
健康2026/09/23@HealthDesk
Eli Lilly Becomes the First Drugmaker Worth $1 Trillion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2025/11/21已确认可信度 87%306天前BioPharma Dive^[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's^[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.
Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.
0.63
健康2026/09/23@HealthDesk
礼来2026年第三季度财报电话会议
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/10/29 14:00预估可信度 71%36天后礼来尚未确认日期（截至2026年9月22日，没有发布“礼来确认2026年第三季度业绩发布日期及电话会议”的公告；第二季度的公告于7月22日发布，定于8月5日）。Public.com^[2]和Nasdaq^[3]将第三季度财报列为“预计”于2026年10月29日“开盘前”发布，这与礼来一贯的节奏（2025年第三季度于2025年10月30日公布）以及其电话会议“将于美东时间上午10点开始”的惯例相符——因此定为2026年10月29日10:00 ET（14:00 UTC），在礼来发布确认公告前均为估计时间。
礼来预计将于10月29日公布2026年第三季度业绩，并照例在美东时间上午10点召开电话会议。此前第二季度营收在Mounjaro和Zepbound带动下增长48%至230亿美元，公司将2026年全年营收指引上调至850亿至870亿美元。
0.62
企业2026/09/23@HealthDesk
J&J Completes Its $1 Billion Acquisition of Firefly Bio
South San Francisco, San Mateo County, California, United StatesJohnson & Johnson…
开始于 2026/07/29已确认可信度 87%56天前"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ^[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".
Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.
$1B
0.62
健康2026/09/23@HealthDesk
礼来在休斯敦Generation Park动工建设65亿美元Foundayo工厂
Eli Lilly…North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United States
开始于 2026/09/21已确认可信度 84%前天礼来的新闻稿标注日期为“HOUSTON^[4], Sept. 21, 2026”，并称礼来“今日在德克萨斯州休斯敦动工”；Community Impact^[2]报道动工仪式于9月21日举行。
这座占地236英亩的工厂将生产礼来减重药Foundayo的活性成分，将带来600多个长期岗位和约4,000个建筑岗位。礼来预计2030年前投产。
$6.5B
0.60
健康2026/09/20@HealthDesk
MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out
Sanofi…Paris, Grand Paris, France
开始于 2028/03/13预估可信度 50%1.5年后ClinicalTrials.gov^[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m
0.59
健康2026/09/23@HealthDesk
FDA批准礼来Inluriyo联合Verzenio用于ESR1突变乳腺癌
Eli Lilly…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States
开始于 2026/09/18已确认可信度 85%5天前礼来的新闻稿标注发稿地与日期为“印第安纳波利斯，2026年9月18日”，并称公司“今日宣布美国食品药品监督管理局（FDA^[4]）已给予完全批准”；FDA自身的公告也将批准日期列为2026年9月18日。
这一全口服组合在EMBER-3试验中将ESR1突变患者的中位无进展生存期从5.5个月翻倍至11.1个月。这是Inluriyo不到一年内获得的第二项FDA批准。
0.59
健康2026/09/23@HealthDesk
Abbott Settles DOJ Infant Formula Claims for $385 Million
Abbott Laboratories…Sturgis, Saint Joseph County, Michigan, 49091, United States
开始于 2026/09/14已确认可信度 88%9天前The release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]
Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.
$385M
0.58
企业2026/09/23@HealthDesk
Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
开始于 2026/09/11已确认可信度 82%12天前The disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's^[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.
Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.
$20B
0.58
健康2026/09/23@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
开始于 2026/01/08已确认可信度 86%258天前J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.57

相似图钉

参考资料 5可信度 87%

建议更正

评论

串

相似图钉